Prime Medicine, Inc. (PRME)
NASDAQ: PRME · Real-Time Price · USD
3.130
-0.090 (-2.80%)
At close: Jul 17, 2026, 4:00 PM EDT
3.140
+0.010 (0.32%)
Pre-market: Jul 20, 2026, 5:39 AM EDT
Prime Medicine Stock Forecast
Stock Price Forecast
According to 13 analysts polled by S&P Global, Prime Medicine stock has a consensus rating of "Buy" and an average price target of $7.12. The average 1-year stock price forecast is 127.48% higher than the current stock price, while the lowest is $4.25 (+35.78%) and the highest is $11 (+251.44%).
Price Target: $7.12 (+127.48%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Prime Medicine stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 8 | 8 | 8 | 9 | 9 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 4 | 4 | 4 | 4 | 3 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 11 | 13 | 13 | 13 | 13 | 13 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Morgan Stanley | Morgan Stanley | Hold Maintains n/a | Hold | Maintains | n/a | n/a | Jul 9, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $10 → $8 | Buy | Reiterates | $10 → $8 | +155.59% | Jul 9, 2026 |
| LifeSci Capital | LifeSci Capital | Buy Maintains $6 | Buy | Maintains | $6 | +91.69% | Jul 8, 2026 |
Unknown Analyst Wedbush No rating | Wedbush | Buy Maintains $8 | Buy | Maintains | $8 | +155.59% | Jun 23, 2026 |
| Oppenheimer | Oppenheimer | Buy Reiterates $11 | Buy | Reiterates | $11 | +251.44% | May 12, 2026 |
Financial Forecast
Revenue This Year
9.03M
from 4.63M
Increased by 94.95%
Revenue Next Year
18.39M
from 9.03M
Increased by 103.63%
EPS This Year
-0.99
from -1.35
EPS Next Year
-0.84
from -0.99
EPS and Forward PE are based on non-GAAP adjusted numbers.